Ligand Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Ligand Pharmaceuticals has a total shareholder equity of $700.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $787.2M and $86.3M respectively. Ligand Pharmaceuticals's EBIT is $9.8M making its interest coverage ratio -1.4. It has cash and short-term investments of $170.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -1.4x |
| Cash | US$170.31m |
| Equity | US$700.91m |
| Total liabilities | US$86.30m |
| Total assets | US$787.22m |
Recent financial health updates
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Recent updates
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?
Oct 11Ligand's Ailing Remdesivir Cash Cow
Oct 11Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Aug 19Financial Position Analysis
Short Term Liabilities: LGND's short term assets ($237.4M) exceed its short term liabilities ($16.8M).
Long Term Liabilities: LGND's short term assets ($237.4M) exceed its long term liabilities ($69.5M).
Debt to Equity History and Analysis
Debt Level: LGND is debt free.
Reducing Debt: LGND has no debt compared to 5 years ago when its debt to equity ratio was 113.4%.
Debt Coverage: LGND has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: LGND has no debt, therefore coverage of interest payments is not a concern.